Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4405094 · 2 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| LY4405094 Study AT01 (Healthy ISA) | EXPERIMENTAL | LY4405094 or placebo administered intravenously (IV) or subcutaneously (SC) in healthy volunteers. |
| LY4405094 Study AT01 (AD ISA) | EXPERIMENTAL | LY4405094 or placebo administered IV to participants with AD. Florbetapir F 18 or Florbetaben F 18 will be administered IV during amyloid positron emission tomography (PET) scan. |
| LY4405094 Part A: Single-Ascending Dose (SAD) | EXPERIMENTAL | LY4405094 administered intravenously (IV) or subcutaneously (SC) in healthy volunteers. |
| Placebo Part A | PLACEBO_COMPARATOR | Placebo administered IV or SC in healthy volunteers. |
| LY4405094 Part B: Multiple Ascending Dose (MAD) | EXPERIMENTAL | LY4405094 administered IV to participants with AD. Florbetapir F 18 or Florbetaben F 18 will be administered IV during amyloid positron emission tomography (PET) scan. |
| Placebo Part B | PLACEBO_COMPARATOR | Placebo administered IV to participants with AD. Florbetapir F 18 or Florbetaben F 18 will be administered IV during amyloid positron emission tomography (PET) scan. |
| Name | Type | Description |
|---|---|---|
| LY4405094 | DRUG | Administered intravenously (IV) |
| Placebo | DRUG | Administered IV |
| Florbetapir F18 | OTHER | Administered IV |
| Florbetaben F 18 | OTHER | Administered IV |
Participants must meet eligibility criteria below. Additional criteria are specified in the substudy to which the participant will enroll. Inclusion Criteria for Healthy Participants: * Are between 18 and 45 years of age * Have a body mass index (BMI) of 18.0 to 32.0 kilograms per square meter (kg...
Top 20 of 30 competitors
LY4405094 is an investigational small molecule being studied for Alzheimer disease. It is also being evaluated in healthy volunteers as part of early-stage research. Eli Lilly and Company is developing the drug, which is currently in Phase 1 clinical development and has not been approved for any indication.
LY4405094 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. The company is running two Phase 1 trials of the drug in the United States, China, and Japan.
LY4405094 is in Phase 1 clinical development. Two Phase 1 trials are registered, both currently active, with one recruiting and one not yet recruiting. The drug is investigational and has not been approved by the FDA for any use.
LY4405094 is being studied in two Phase 1 trials. NCT07787182 is a study in healthy participants and participants with Alzheimer disease that is not yet recruiting. NCT07787169 is a master protocol studying multiple amyloid-targeting therapies in healthy participants and participants with Alzheimer disease and is currently recruiting.
The two Phase 1 trials of LY4405094 have a combined planned enrollment of 247 participants. NCT07787182 plans to enroll 68 participants, and NCT07787169 plans to enroll 179 participants. Both trials are randomized, double-blind, and placebo-controlled.